Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
342.40
-1.59 (-0.46%)
At close: Nov 19, 2025, 4:00 PM EST
342.40
0.00 (0.00%)
Pre-market: Nov 20, 2025, 8:03 AM EST
Amgen Revenue
Amgen had revenue of $9.56B in the quarter ending September 30, 2025, with 12.40% growth. This brings the company's revenue in the last twelve months to $35.97B, up 10.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$35.97B
Revenue Growth
+10.56%
P/S Ratio
5.12
Revenue / Employee
$1,284,679
Employees
28,000
Market Cap
184.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AMGN News
- 16 hours ago - FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER - PRNewsWire
- 1 day ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 7 days ago - There Are Non-AI Stocks Worth Buying. Start With This List. - Barrons
- 9 days ago - CEO of drugmaker Amgen talks new results from cholesterol drug trial - CNBC
- 11 days ago - AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL - PRNewsWire
- 11 days ago - Amgen cholesterol drug cuts risk of first cardiac event by 25% - Reuters
- 12 days ago - Amgen: Buy This Cheap Biotech Leader - Seeking Alpha
- 13 days ago - Stock Of The Day: Will Amgen Reverse Again? - Benzinga